Ming Jun Shi
Impact in
- Hepatology top 0.2%
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Research top 2%
- Cancer, Hypoxia, and Metabolism
- Cancer, Lipids, and Metabolism
- Cancer-related molecular mechanisms research
Papers in
- Hepatology 73
- Hepatocellular Carcinoma Treatment and Prognosis 70
-
- Ginseng Biological Effects and Applications 16
- Co-authors
- Rong Guo (52 shared papers)Min-Shan Chen (14 shared papers)Jian‐Yong Wu (5 shared papers)Wei Wei (30 shared papers)Yaojun Zhang (13 shared papers)Xiao-Jun Lin (8 shared papers)Li Xu (16 shared papers)Jin-Qing Li (6 shared papers)
- Journals
- PLoS ONE (8 papers)Oncotarget (5 papers)癌症：英文版 (5 papers)Frontiers in Oncology (5 papers)Journal of Hepatology (4 papers)
- Partner nations
- ChinaUnited StatesHong Kong
In The Last Decade
Ming Jun Shi
276 papers receiving 9.5k citations
Ming Jun Shi's Hit Papers
Peers
Comparison fields: 5 of 167
- Hepatology 3.6k
- Cancer Research 1.2k
- Complementary and alternative medicine 382
- Molecular Biology 2.7k
- Oncology 965
Countries citing papers authored by Ming Jun Shi
This map shows the geographic impact of Ming Jun Shi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ming Jun Shi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ming Jun Shi more than expected).
Fields of papers citing papers by Ming Jun Shi
This network shows the impact of papers produced by Ming Jun Shi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ming Jun Shi. The network helps show where Ming Jun Shi may publish in the future.
Co-authors
The 25 scholars most cited alongside Ming Jun Shi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 285 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion Hit paper breakdown → | 2019 | 425 |
| 2 | 2006 | 415 | |
| 3 | Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition) Hit paper breakdown → | 2023 | 305 |
| 4 | 2018 | 295 | |
| 5 | 2010 | 289 | |
| 6 | 2018 | 222 | |
| 7 | 2008 | 202 | |
| 8 | 2012 | 199 | |
| 9 | 2006 | 184 | |
| 10 | 2021 | 161 | |
| 11 | 2004 | 158 | |
| 12 | 2018 | 136 | |
| 13 | 2022 | 130 | |
| 14 | 2010 | 119 | |
| 15 | 2017 | 118 | |
| 16 | 2016 | 115 | |
| 17 | 2015 | 111 | |
| 18 | 2009 | 107 | |
| 19 | 2011 | 102 | |
| 20 | 2011 | 102 |
About Ming Jun Shi
Ming Jun Shi is a scholar working on Hepatology, Molecular Biology, Cancer Research, Pathology and Forensic Medicine and Neurology, having authored 285 papers that have together received 9.7k indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (70 papers), Ginseng Biological Effects and Applications (16 papers), Cancer Mechanisms and Therapy (13 papers), Neurogenesis and neuroplasticity mechanisms (10 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (9 papers), Neuroinflammation and Neurodegeneration Mechanisms (9 papers), Traditional Chinese Medicine Analysis (9 papers) and Cancer, Hypoxia, and Metabolism (8 papers). The work is most often cited by research in Hepatology (3.6k citations), Cancer Research (1.2k citations), Complementary and alternative medicine (382 citations), Molecular Biology (2.7k citations) and Oncology (965 citations). Ming Jun Shi has collaborated with scholars based in China, United States and Hong Kong. Frequent co-authors include Rong Guo, Min-Shan Chen, Jian‐Yong Wu, Wei Wei, Yaojun Zhang, Xiao-Jun Lin, Li Xu, Jin-Qing Li, Wan Yee Lau and Minke He. Their work appears in journals such as PLoS ONE, Oncotarget, 癌症：英文版, Frontiers in Oncology and Journal of Hepatology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.